L1CAM as a Negative Prognostic Factor in Endometrioid Endometrial Adenocarcinoma FIGO Stage IA-IB.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 04 11 2018
revised: 19 11 2018
accepted: 21 11 2018
entrez: 29 12 2018
pubmed: 29 12 2018
medline: 8 1 2019
Statut: ppublish

Résumé

In this study, we aimed to investigate how positivity for L1 cell adhesion molecule (L1CAM) was associated with outcome and relapse pattern in patients with Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) stage IA-IB endometrial cancer. This retrospective study included 358 patients who underwent surgical treatment for endometrial carcinoma. Tumor samples from 312 patients (87.2%) were available for L1CAM analysis by immunohistochemistry. Of the 312 tumor samples analyzed, 93 (29.8%) were L1CAM-positive. L1CAM positivity was significantly more common in grade 3 compared to grade 1-2 carcinomas (p=0.02). Patients with L1CAM positivity more commonly experienced disease progression. Distant metastasis was significantly associated with L1CAM positivity (p=0.01). Progression-free interval and overall survival did not significantly differ between L1CAM-positive and L1CAM-negative cases. L1CAM is a promising independent prognostic marker associated with aggressive tumor behavior and recurrence risk, but not with overall survival.

Identifiants

pubmed: 30591489
pii: 39/1/421
doi: 10.21873/anticanres.13128
doi:

Substances chimiques

Biomarkers, Tumor 0
Neural Cell Adhesion Molecule L1 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

421-424

Informations de copyright

Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Jaroslav Klat (J)

Department of Obstetrics and Gynecology, University Hospital Ostrava, Ostrava Poruba, Czech Republic jaroslav.klat@fno.cz.

Ales Mladenka (A)

Department of Obstetrics and Gynecology, University Hospital Ostrava, Ostrava Poruba, Czech Republic.

Jana Dvorackova (J)

Institute of Pathology, University Hospital Ostrava, Ostrava Poruba, Czech Republic.

Sylva Bajsova (S)

Department of Obstetrics and Gynecology, University Hospital Ostrava, Ostrava Poruba, Czech Republic.

Ondrej Simetka (O)

Department of Obstetrics and Gynecology, University Hospital Ostrava, Ostrava Poruba, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH